1stOncology™: Cancer Intelligence Service – Page 49 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival

On June 1, 2026 Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, reported positive preclinical data will be presented at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting demonstrating that DNase I significantly enhances CAR-T cell expansion, persistence, and antitumor efficacy in aggressive hematologic cancer models.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Presentation Details:

Session Title: Hematologic Malignancies – Plasma Cell Dyscrasia (Poster Session)

Abstract Title: Targeting cfDNA and NETs with DNase I to augment CAR-T cell function and antitumor efficacy

Poster Board: 410

Presentation Date & Time: June 1, 2026, 9:00 AM – 12:00 PM CDT

Presenter: Alexey V. Stepanov, PhD

The poster presentation, titled "Targeting cfDNA and NETs with DNase I Augments CAR T-Cell Function and Antitumor Efficacy," highlights evidence that extracellular DNA and neutrophil extracellular traps (NETs) act as key drivers of CAR-T cell exhaustion and persistence, leading to therapeutic failure. The findings demonstrate that DNase I degrades these immunosuppressive barriers and restores CAR-T functionality.

In preclinical studies, DNase I efficiently degraded extracellular DNA, preserved CAR-T cell effector function, improved CD8-positive T cell ratios and reduced expression of exhaustion markers including PD-1, LAG-3 and TIM-3 across multiple rounds of tumor rechallenge in vitro.

In vivo, DNase I significantly enhanced CAR-T cell expansion and persistence following infusion in both NALM-6 B cell leukemia and Raji Burkitt lymphoma xenograft models. Combination therapy with DNase I resulted in improved tumor control, delayed relapse upon rechallenge and prolonged survival compared to CAR T-cell therapy alone.

The poster also includes translational observations from a pediatric patient with highly refractory Burkitt lymphoma, where DNase I co-administration was associated with marked CAR-T cell expansion and progressive reduction in tumor burden following prior CAR-T cell failure.

"These findings continue to strengthen the growing body of evidence implicating extracellular DNA and NETs as important contributors to immune suppression and therapeutic resistance in cancer," said James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic Biosciences. "We believe these data highlight the potential for DNase I to serve as a differentiated adjunctive immuno-oncology strategy capable of improving CAR T-cell persistence and durability across difficult-to-treat hematologic malignancies."

The findings further support Xenetic’s broader DNase-based immuno-oncology platform designed to improve outcomes of existing cancer therapies, including immunotherapies and cell therapies, through targeting NET-driven immune suppression within the tumor microenvironment.

(Press release, Xenetic Biosciences, JUN 1, 2026, View Source [SID1234666321])

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

On June 1, 2026 Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, reported the U.S. commercial launch of the Prosigna Breast Risk of Recurrence (ROR) test, a genomic test for patients diagnosed with early-stage hormone-receptor positive (HR+) breast cancer. The Prosigna test determines a patient’s ROR score and estimates the 10-year probability of distant recurrence, providing prognostic insight into how a patient’s cancer may behave over time. These insights also help guide treatment decisions, including predicting whether high risk patients are likely to benefit from chemotherapy or may safely achieve optimal outcomes with endocrine therapy alone, enabling clinicians to make personalized care plans for their patients. The Prosigna test will be available to order starting June 8, 2026.

"Every patient diagnosed with breast cancer deserves answers they can trust about what their cancer means and what comes next," said John Leite, PhD, chief commercial officer, Veracyte. "Prosigna gives patients and their oncologists a deeper understanding of their individual risk of recurrence, and, for many, whether chemotherapy will truly benefit them or whether they can safely avoid it. That kind of personalized insight can bring greater confidence and reassurance as patients navigate decisions that will shape their care and future health."

In the U.S., more than 225,000 new HR+/HER2- breast cancer cases are diagnosed each year. When breast cancer is diagnosed early and treated appropriately, five-year survival rates reach 92%.1 It is critically important to accurately determine a patient’s risk of recurrence because the effects of treatment escalation or de-escalation have a lasting impact on a patient’s life.

Introducing the Prosigna Test: Prediction that adds up

The Prosigna test is the only breast cancer test that factors a patient’s biological, clinical, and pathological information into a single comprehensive analysis. The test uniquely combines intrinsic subtypes and proliferation score with clinical factors to determine a patient’s ROR score and predict the 10-year probability of distant recurrence. This long-term risk assessment provides clinically meaningful insight beyond initial diagnosis, particularly in early-stage breast cancer where recurrence can occur many years later.

For decades, clinical risk factors have been a key factor in treatment decisions. Currently, for many patients with high-risk breast cancer who are premenopausal and node positive, standard of care is still chemotherapy and endocrine therapy. New data from the OPTIMA trial shows that nodal involvement and other clinical risk factors do not automatically equate to high risk of recurrence — for the first time, more than two-thirds of node-positive patients who previously might have received chemotherapy can now safely avoid it based on the Prosigna test results.

Why the Prosigna test stands apart:

Comprehensive molecular analysis: The Prosigna test was developed from the PAM50 genomic classifier, a foundation for understanding breast cancer biology, which classifies a patient’s individual tumor into one of the four intrinsic subtypes. The Prosigna test is the only test that combines intrinsic subtypes and proliferation score with clinical pathological factors to provide a comprehensive 10-year probability of distant recurrence.
Proven across high-risk populations: The Prosigna test is the only test proven to be predictive for chemotherapy benefit decisions in a phase III prospective trial for premenopausal and postmenopausal women with high-risk breast cancer, including those with extensive nodal involvement (up to 9 positive nodes).
Superior prognostic accuracy: Extensively validated clinical evidence demonstrates that the Prosigna test is more prognostically accurate than other genomic assays, particularly in the critical 5-10 year breast cancer recurrence window.2, 3
"The PAM50 signature was designed to unlock the clinical utility of modern biological insights into the nature of breast cancer. Through the Prosigna test, these biological insights are now directly informing treatment decisions for patients," said Matthew Ellis, M.D., Ph.D., one of the developers of the PAM50-based Prosigna test. "The OPTIMA results reinforces the need to ground critical decisions upon tumor biology because understanding risk of recurrence and chemotherapy benefit as distinct principles produces safer and more personalized care."

"Patients diagnosed with early-stage breast cancer deserve access to the most advanced testing available, with the most up to date evidence, so they can make informed treatment decisions with their medical oncology team," said Jean Sachs, MSS, MLSP Chief Executive Officer of Living Beyond Breast Cancer. "Prosigna’s ability to accurately predict risk of recurrence means patients may have the option to avoid chemotherapy and its significant side effects or confidently pursue more aggressive treatment when it will truly benefit them. That is what we want for everyone diagnosed with breast cancer – a personalized treatment plan that is informed by the most up-to-date data."

Veracyte is committed to making the Prosigna test accessible to all eligible breast cancer patients. The test is currently covered by most commercial payers, and patients may qualify for financial assistance or a tailored payment plan supported by the Veracyte Access Program for eligible uninsured and underinsured patients. The Prosigna test will be available for ordering starting June 8, 2026 through Veracyte’s network nationwide via the easy-to-use Veracyte Ordering Portal. For ordering information and clinical resources, visit www.veracyte.com/prosigna.

(Press release, Veracyte, JUN 1, 2026, View Source [SID1234666320])

UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

On June 1, 2026 UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, reported that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference to take place on June 8-10, 2026.

Goldman Sachs 47th Annual Global Healthcare Conference

Date / Time: June 10, 2026, at 8:40 AM ET
Format: Fireside chat and 1×1 investor meetings
Location: Miami Beach, FL
Webcast Link: here

The webcast from the conference will also be available on UroGen’s corporate website, under Events & Presentations. A replay will be available for approximately 90 days.

(Press release, UroGen Pharma, JUN 1, 2026, View Source [SID1234666319])

Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026

On June 1, 2026 Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, reported that it will host an R&D Day on Tuesday, July 14, 2026, at 8:30 AM ET in New York City. The R&D Day will feature presentations by Syndax’s management team and key opinion leaders.

The Company will highlight its late-stage revumenib and axatilimab programs, including its ongoing trials in idiopathic pulmonary fibrosis, newly diagnosed chronic graft-versus-host disease, and newly diagnosed acute leukemia. Further, the Company will detail its new early-stage assets and broader plans to leverage its capabilities and resources to bring new treatment options to more patients.

A live webcast of the event will be available on the Investor section of the Company’s website at www.syndax.com, where a replay of the event will also be available for a limited time.

(Press release, Syndax, JUN 1, 2026, View Source [SID1234666318])

The European Commission approves PharmaMar’s Zepzelca® (lurbinectedin) for the treatment of extensive-stage small cell lung cancer in combination with atezolizumab

On June 1, 2026 PharmaMar (MSE: PHM), reported that the European Commission (EC) has approved the combination of Zepzelca (lurbinectedin) with atezolizumab (Tecentriq) as a first-line maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC), whose disease has not progressed following standard induction therapy. This approval follows the positive opinion issued on March 27th by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) concerning this treatment.

Luis Mora, Managing Director of PharmaMar, points out that "it is great news that European patients and doctors now have access to a new treatment for this type of cancer. We believe it has the potential to change the paradigm of treatment for this disease, so we are looking forward to it being available soon in hospitals across Europe."

The approval is based on data from the Phase 3 IMforte trial, sponsored by Roche in collaboration with Jazz Pharmaceuticals, in which the combination of lurbinectedin and atezolizumab as maintenance treatment in first-line ES-SCLC was associated with a 46% reduction in the risk of disease progression or death and a 27% reduction in the risk of death compared with atezolizumab monotherapy.

In addition, lurbinectedin has been approved as an orphan drug, a designation granted by the EMA to medicines intended for the treatment of rare or uncommon diseases affecting fewer than 5 people per 10,000 inhabitants in the European Union.

Each year, around 62,000 new cases of SCLC are diagnosed in Europe, with most patients presenting advanced disease at the time of diagnosis .

Lurbinectedin in combination with atezolizumab has already been approved in 13 other countries, including the United States, for first-line maintenance treatment of this disease.

(Press release, PharmaMar, JUN 1, 2026, View Source [SID1234666317])